NEW YORK, March 8, 2017 /PRNewswire/ --
On Tuesday, March 07, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the
S&P 500 edged lower at the closing bell. Six out of nine sectors ended Tuesday's trading session in bearish territories.
Taking into consideration yesterday's market sentiment, Stock-Callers.com assessed the following Biotech equities this morning:
bluebird bio Inc. (NASDAQ: BLUE), Opexa Therapeutics Inc. (NASDAQ: OPXA), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), and PTC
Therapeutics Inc. (NASDAQ: PTCT). Download the free research reports on these stocks today:
http://stock-callers.com/registration
bluebird bio
Cambridge, Massachusetts headquartered bluebird bio Inc.'s stock finished Tuesday's session
1.44% lower at $82.30 with a total volume of 774,955 shares traded. Over the last one month and the
previous three months, bluebird bio's shares have advanced 4.64% and 17.99%, respectively. Furthermore, the stock has surged
49.31% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 13.63% and 38.36%,
respectively. Shares of bluebird bio, which focuses on developing transformative gene therapies for severe genetic diseases and
cancer in Cambridge, Massachusetts and Seattle, Washington,
have a Relative Strength Index (RSI) of 54.97.
On February 27 th, 2017, research firm Maxim Group downgraded the Company's stock
rating from 'Buy' to 'Hold'. See our free and comprehensive research report on BLUE at:
http://stock-callers.com/registration/?symbol=BLUE
Opexa Therapeutics
The Woodlands, Texas-based Opexa Therapeutics Inc.'s stock fell 2.91%, to close the day at
$0.91. The stock recorded a trading volume of 40,756 shares. Opexa Therapeutics' shares are trading
7.64% and 64.08% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which develops
personalized immunotherapy to treat multiple sclerosis and other autoimmune diseases based on its proprietary T-cell technology,
have an RSI of 40.49. OPXA free research report PDF is just a click away at:
http://stock-callers.com/registration/?symbol=OPXA
Agios Pharma
On Tuesday, shares in Cambridge, Massachusetts headquartered Agios Pharmaceuticals Inc. ended
the session 0.72% lower at $49.57 with a total volume of 360,086 shares traded. Agios Pharma's
shares have gained 12.92% in the last one month and 3.88% in the previous one year. The stock is trading 10.52% above its 50-day
moving average and 3.67% above its 200-day moving average. Moreover, shares of the Company, which engages in the discovery and
development of medicines for the treatment of cancer and rare genetic metabolic disorders in the US, have an RSI of 54.24. Sign
up for your complimentary report on AGIO at:
http://stock-callers.com/registration/?symbol=AGIO
PTC Therapeutics
On Tuesday, shares in South Plainfield, New Jersey headquartered PTC Therapeutics Inc.
recorded a trading volume of 1.11 million shares, which was higher than their three months average volume of 962,790 shares. The
stock ended the day 2.84% lower at $9.93. PTC Therapeutics' stock has surged 53.24% in the past one
year. The Company is trading above its 200-day moving average by 0.59%. Furthermore, shares of PTC Therapeutics, which focuses on
the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional
control processes, have an RSI of 31.54.
On March 03 rd, 2017, research firm Barclays downgraded the Company's stock rating
from 'Overweight' to 'Equal Weight' while revising its previous target price from $20 a share to
$13 a share. Register for free on Stock-Callers.com and download the latest research report on PTCT
at:
http://stock-callers.com/registration/?symbol=PTCT
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES :
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you ' re
a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone
between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA